Summit Therapeutics Provides Notice of Full Year Financial Results
May 01 2015 - 1:00AM
Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug
discovery and development company advancing therapies for Duchenne
muscular dystrophy and C. difficile infection, will be announcing
its full year financial results for the year ended 31 January 2015
on Wednesday 6 May 2015.
Summit will host a conference call the same day at 1:00pm BST /
8:00am EDT. Conference call information will be included in the
full year results press release, and a replay of the call will also
be available through the Company's website, www.summitplc.com.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialization of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease Duchenne muscular dystrophy and the infectious
disease C. difficile infection. Further information is available at
www.summitplc.com and Summit can be followed on Twitter
(@summitplc).
For more information, please contact:
Summit Therapeutics) |
|
Glyn Edwards / Richard Pye
(UK office |
Tel: +44 (0)1235 443 951 |
Erik Ostrowski (US office) |
+1 617 294 6607 |
|
|
Cairn Financial Advisers
LLP |
|
(Nominated Adviser) |
|
Liam Murray / Tony Rawlinson |
Tel: +44 (0)20 7148 7900 |
|
|
N+1 Singer |
|
(Broker) |
|
Aubrey Powell / Jen Boorer |
Tel: +44 (0)20 7496 3000 |
|
|
MacDougall Biomedical
Communications |
|
(US media contact) |
Tel: +1 781 235 3060 |
Michelle Avery |
mavery@macbiocom.com |
|
|
Peckwater PR |
|
(Financial public relations, UK) |
Tel: +44 (0)7879 458 364 |
Tarquin Edwards |
tarquin.edwards@peckwaterpr.co.uk |
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024